menu
    • menu

    Company profile for BrightGene Bio-Medical Technology Co.,Ltd

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Aurigene is a global leader in accelerating drug innovation through discovery, development & manufacturing.

    Virtual Booth

    Contact Supplier

    Midas Pharma provides expertise in developing and supplying APIs, finished products, and intermediates.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-01-06

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    BrightGene Bio-Medical Technology Co., Ltd. is a research driven biopharmaceutical company that engages in the R&D and manufacturing of innovative medicine as well as special generic APIs and FDFs with primary strategic focus on the regulated market. We have an exciting and very promising innovative pipeline including immuno-oncological therapeutic agents, orally available GLP-1RA peptides for type 2 diabetes, antibody drug co...
    BrightGene Bio-Medical Technology Co., Ltd. is a research driven biopharmaceutical company that engages in the R&D and manufacturing of innovative medicine as well as special generic APIs and FDFs with primary strategic focus on the regulated market. We have an exciting and very promising innovative pipeline including immuno-oncological therapeutic agents, orally available GLP-1RA peptides for type 2 diabetes, antibody drug conjugates for solid tumor, novel non-antibody dependent tumor targeting conjugates for brain cancer and solid tumor brain-metastasis.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    BrightGene Bio-Medical Technology Co.,LtdChina Flag
    Country
    Country
    China
    Address
    Address
    Suzhou Industrial Park, Jiangsu Province
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.bright-gene.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/brightgene-bio-medical-technology-co.-ltd/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    INTERVIEW #SpeakPharma

    [Sponsored by another company]
    “Translational Pharmaceutics, our flagship platform for drug development, empowers our clients with unparalleled flexibility”

    “Translational Pharmaceutics, our flagship platform for drug development, empowers our clients with unparalleled flexibility”

    This week, SpeakPharma interviews Denise Sutton, Chief Operating Officer and Site Head at Quotient Sciences’ Nottingham facility in the UK. Quotient Sciences is a drug development and manufacturing accelerator that offers the innovative Translational Pharmaceutics platform to support customers in overcoming drug development challenges. Sutton has been with the company for over 25 years. In this interview, she provides insights into the evolution of Quotient Sciences’ Nottingham facility and discusses how the organization has transformed from a small 10-bed clinic to a comprehensive drug development campus with six GMP suites. She also shares her perspective on the company’s unique approach to integrating drug development services. HIGHLIGHTS// evolution of Quotient Sciences’ Nottingham facility/ unique approach to integrating drug development services How has the Nottingham site transformed from when it was founded, to what it is today? Initially, we were a small company with fewer than 50 employees, a 10-bed clinic, and a single lab. Over 90 percent of our work focused on gamma scintigraphic imaging (a diagnostic test that creates images of the body’s internal organs and tissues using gamma rays). Due to the short half-life radionuclides we used to label dosage forms, every product we manufactured had a limited time to be dosed. At the end of 1999, we moved our headquarters to a purpose-built, two-storey facility—now known as Trent House on our now much larger Nottingham campus. We built three good manufacturing practice (GMP) suites on the top floor and three clinical wards on the bottom floor. These were very early days that marked the start of our Translational Pharmaceutics platform. We continued to expand the range of scintigraphy applications we offered in response to changing customer requirements until, in 2008, when we approached the MHRA (UK’s Medicines and Healthcare products Regulatory Agency) with a new request. We asked if it might be possible to work at the same pace as we did in our scintigraphic imaging studies, but do so for conventional drug development, without the radiolabel. We explored the application of ICH Q8 Quality by Design (QbD) guidelines to introduce a compositional design space into the CMC section of our regulatory dossier. This officially created a methodology for applying the Translational Pharmaceutics platform, and we haven't looked back since. Today, we have expanded substantially. Our Nottingham site is a campus of five buildings. We have development and analytical labs, six GMP suites, six clinical wards with a total of 85 beds (where we conduct healthy volunteer phase 1 clinical studies), and many talented colleagues covering our spectrum of CRO and CDMO services. HIGHLIGHTS// officially created a methodology for applying the Translational Pharmaceutics platform/ development and analytical labs/ six GMP suites   How is Translational Pharmaceutics applied to drug development programs? We apply Translational Pharmaceutics across three core applications: first-in-human clinical studies, drug product optimization programs through rapid formulation development and clinical testing, and as a part of human ADME (absorption, distribution, metabolism, and excretion) programs. No matter how a client chooses to work with us to apply Translational Pharmaceutics, the benefits of using a single organization and project management team to integrate services lets our clients remain in control and one step ahead of the emerging data that impacts the success of their molecule. Over all these years, our flagship Translational Pharmaceutics platform for drug development has remained unchanged in the way it empowers our customers and offers them unparalleled flexibility. HIGHLIGHTS// three core applications/ benefits of using a single organization/ clients remain in control   What would you say are the key strengths of Quotient Sciences’ Nottingham site? How do you support customer programs? Nowhere else would a single project manager oversee such a broad spectrum of activities, let alone be expected to ensure seamless, timely progression across functions that in any other company (i.e. at other CDMOs or CROs) would be delivered through multiple operating areas or through the use of a combination of third-party vendors. The project managers do face challenges. But by working with the project team, they are able to anticipate, avoid, and mitigate any impact whenever necessary. We know that time is incredibly valuable for our customers. A project Gantt chart is our project management team’s guiding light. I believe our project management team is truly world-leading – they communicate well, show great compassion, and lead with integrity. I’m super proud of our high-performing, supportive, cross-functional teams that support our customers when they trust their molecules to us, and work collaboratively to deliver the best possible service. After 25 years at Quotient, I continue to really enjoy going to work. I am indebted to various colleagues for helping me continue to feel this way. HIGHLIGHTS// project management team is truly world-leading/ high-performing, supportive, cross-functional teams/ 25 years at Quotient  

    Impressions: 4916

    subscribeSubscribe

    https://www.pharmacompass.com/speak-pharma/translational-pharmaceutics-our-flagship-platform-for-drug-development-empowers-our-clients-with-unparalleled-flexibility

    Radio Compass
    16 Dec 2024
    Share info Share

    VLOG #PharmaReel

    [Sponsored by another company]

    DATA COMPILATION #PharmaFlow

    [Sponsored by another company]
    BMS, J&J, Bayer lead 25,000+ pharma layoffs in 2024; Amylyx, FibroGen, Kronos Bio hit by trial failures, cash crunch

    BMS, J&J, Bayer lead 25,000+ pharma layoffs in 2024; Amylyx, FibroGen, Kronos Bio hit by trial failures, cash crunch

    Since 2022, there has been a significant surge in layoffs by pharmaceutical and biotech companies. While this trend continued into 2024, the industry showed signs of stabilization in the last four months of the year with the pace of layoffs slowing down. Nonetheless, 2024 was a challenging year. Data compiled by PharmaCompass indicates that over 25,000 layoffs were announced in 2024, driven by economic pressures, failed clinical trials, and strategic pivots. Bristol Myers Squibb and Johnson & Johnson led the layoffs with about 2,300 job cuts each. Bayer announced elimination of 1,800 positions.  View Our Interactive Dashboard on Biopharma Layoffs in 2024 (Free Excel Available) US, Europe, China bear brunt of job cuts; Big Pharma hands pink slips to 10,000 Over 190 biopharma companies announced layoffs in 2024. The year began on a grim note — 27 firms announced significant job cuts in January 2024. By the yearend, Big Pharma alone had contributed more than 10,000 layoffs to the year’s total of over 25,000. Novartis announced over 1,200 job cuts in 2024. It eliminated 330 jobs after it acquired German biotech MorphoSys through the closure of sites in Munich and Boston. Similarly, Bayer announced significant reductions at its US and Swiss facilities.  North America saw increased retrenchments, especially at biotech hubs such as Boston, San Diego, and New Jersey. Massachusetts, with Boston and Cambridge as the epicenter of US biotechnology, saw around 4,000 layoffs, with companies like Relay Therapeutics, Editas Medicine, and Takeda driving the numbers. In San Diego, workforce reductions by Takeda, and Bavarian Nordic collectively resulted in over 900 job losses, significantly impacting the local biotech ecosystem. New Jersey was subject to broader restructuring efforts with BMS and Bayer contributing nearly 1,500 layoffs. The impact in Europe was equally severe. Germany, home to some of the world’s largest pharmaceutical companies, saw over 2,500 layoffs as Bayer and Boehringer Ingelheim scaled back operations. Novartis’ decision to shut down its Munich site added hundreds more to the tally. In Switzerland, Idorsia eliminated 270 positions. Dutch biotech UniQure reduced its workforce by 65 percent (around 300 jobs). That included the sale of a Massachusetts manufacturing facility to Genezen. Denmark also felt the strain, with Leo Pharma cutting 250 roles as part of a strategic revamp. China emerged as another focal point of workforce reductions in 2024. Global pharmaceutical giants, such as Merck and Johnson & Johnson, restructured their operations in response to market complexities in the region. Local companies such as Connect Biopharma, which is transitioning to a US-focused company, also scaled back their presence in the country.  View Our Interactive Dashboard on Biopharma Layoffs in 2024 (Free Excel Available)  Amylyx, FibroGen, Lyra, Athira drastically reduce staff over setbacks in clinical trials Clinical trial failures were one of the most significant drivers of layoffs in 2024. For instance, Amylyx Pharmaceuticals faced a devastating blow when its amyotrophic lateral sclerosis (ALS) therapy, Relyvrio, failed a confirmatory trial. This led to a 70 percent reduction in its workforce, leaving only 100 employees from the 384 full-time staff reported at the end of 2023. The company’s decision to pull the therapy from the market compounded the layoffs. BioMarin Pharmaceutical had to reduce its workforce, as it streamlined its pipeline in response to trial challenges. In August, the company announced a reduction of 225 employees, citing “organizational redesign efforts”. These layoffs followed 170 redundancies announced earlier in May. FibroGen, once considered a leader in oncology drug development, was among the most heavily impacted. The high-profile failure of its anti-CTGF antibody in two late-stage cancer trials led to the discontinuation of its lead candidate, resulting in a 75 percent reduction in its US workforce. Lyra Therapeutics also implemented a 75 percent workforce reduction, affecting 87 employees, after its chronic rhinosinusitis program struggled. Similarly, Athira Pharma cut 70 percent of its team after its Alzheimer’s candidate failed a phase 2/3 trial.  View Our Interactive Dashboard on Biopharma Layoffs in 2024 (Free Excel Available)  Cash crunch, mergers compel Kronos Bio, Editas, Vincerx, Gilead to downsize In addition to clinical failures, funding constraints played a pivotal role in reshaping the biotech landscape. Kronos Bio stood out as one of the hardest-hit firms, cutting 21 percent and 83 percent of its existing workforce in March and November, respectively, as it sought to divest assets and conserve cash. Editas Medicine’s inability to secure partnerships for its sickle cell program forced the company to revert to preclinical research, resulting in a 65 percent workforce reduction. The trend of scaling back R&D pipelines was particularly evident among biotechs struggling to advance preclinical programs to clinical trials. Boundless Bio and Senti Bio exemplified this, choosing to focus on a handful of promising candidates, while reducing discovery efforts. Consolidation often results in overlapping roles, leading to inevitable workforce reductions. Apart from the MorphoSys layoffs by Novartis, Vincerx Pharma faced job losses after it got acquired by Oqory (a clinical-stage ADC company). Vincerx had to cut its workforce by 55 percent.  Amid ongoing reorganization efforts, Gilead closed its Seattle, Washington (US), office and laid off 72 employees of its subsidiary Kite Pharma. Gilead also announced that its Kite facility in Philadelphia, Pennsylvania (US), would close by mid-2025. That was followed by 104 additional layoffs at its California headquarters. In April, it had cut 58 jobs in California. Gilead also announced that its Kite facility in Philadelphia would close by mid-2025. Vir Biotechnology reduced its workforce by 25 percent (i.e. 140 layoffs) to focus on its hepatitis program, and GlycoMimetics let go of 80 percent of its workforce after the FDA demanded an additional clinical trial for its leukemia treatment. Meanwhile, Lexicon Pharmaceuticals reduced its workforce by 60 percent after it stopped commercial operations and transitioned back to being a clinical stage company.  View Our Interactive Dashboard on Biopharma Layoffs in 2024 (Free Excel Available)  Our view It takes decades to build innovation ecosystems. The concentration of layoffs in major biotech hubs has raised concerns about the potential long-term impact on these ecosystems. In 2025, the key challenge will be to maintain the momentum of innovation, as organizations operate with a leaner workforce and a more focused pipeline.  
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 4560

    https://www.pharmacompass.com/radio-compass-blog/bms-j-j-bayer-lead-25-000-pharma-layoffs-in-2024-amylyx-fibrogen-kronos-bio-hit-by-trial-failures-cash-crunch

    #PharmaFlow by PHARMACOMPASS
    16 Jan 2025
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    A Chinese company is already mass producing Gilead's experimental coronavirus drug
    A Chinese company is already mass producing Gilead's experimental coronavirus drug

    13 Feb 2020

    // Jason Mast ENDPTS

    https://endpts.com/a-chinese-company-is-already-mass-producing-gileads-experimental-coronavirus-drug/

    Jason Mast ENDPTS
    13 Feb 2020
    Share Share
    China’s BrightGene successfully copies Gilead’s coronavirus hopeful remdesivir
    China’s BrightGene successfully copies Gilead’s coronavirus hopeful remdesivir

    13 Feb 2020

    // Lucy Parsons PMLIVE

    http://www.pmlive.com/pharma_news/chinas_brightgene_successfully_copies_gileads_coronavirus_hopeful_remdesivir_1325639

    Lucy Parsons PMLIVE
    13 Feb 2020
    Share Share
    Brightgene Bio-Medical's Generic Entecavir Receives Approval In US
    Brightgene Bio-Medical's Generic Entecavir Receives Approval In US

    25 Sep 2019

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212126

    FDA
    25 Sep 2019
    Share Share

    USDMF

    read-more
    read-more

    01

    ((3s,5r)-5-((1h-1,2,4-triazol-1-yl)m...

    China
    Pharma, Lab & Chemical Expo
    Not Confirmed
    arrow

    02

    2-amino-1,9-dihydro-9-[(1s,3r,4s)-4-...

    China
    Pharma, Lab & Chemical Expo
    Not Confirmed
    arrow

    03

    2-[(1s,2s)-1-ethy1-2-bezyloxypropyl]...

    China
    Pharma, Lab & Chemical Expo
    Not Confirmed
    arrow

    04

    Anidulafungin (non-sterile Api)

    China
    Pharma, Lab & Chemical Expo
    Not Confirmed
    arrow

    05

    Ansamitocin P-3

    China
    Pharma, Lab & Chemical Expo
    Not Confirmed
    arrow

    06

    Argatroban

    China
    Pharma, Lab & Chemical Expo
    Not Confirmed
    arrow

    07

    Carboprost Tromethamine

    China
    Pharma, Lab & Chemical Expo
    Not Confirmed
    arrow

    08

    Caspofungin Acetate (dkb)

    China
    Pharma, Lab & Chemical Expo
    Not Confirmed
    arrow

    09

    Dalbavancin Hydrochloride

    China
    Pharma, Lab & Chemical Expo
    Not Confirmed
    arrow

    10

    Dalbavancin Hydrochloride (db)

    China
    Pharma, Lab & Chemical Expo
    Not Confirmed
    arrow
    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Inspections and registrations

    Upload your audits for free, ask us

    FDA

    read-more
    read-more

    01

    FDA Audited

    USA
    Pharma, Lab & Chemical Expo
    Not Confirmed
    arrow

    FDA Audited

    USA
    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed

    District Decision : Voluntary Action Indicated

    Inspection End Date : 2013-03-14

    BrightGene Bio-Medical Technology Co.,Ltd

    City : Suzhou

    State :

    Country/Area : CN

    Zip :

    District : ORA

    Center : CDER

    Project Area : Drug Quality Assurance

    District Decision : Voluntary Action Indicated

    Inspection End Date : 2013-03-14

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    02

    FDA Audited

    USA
    Pharma, Lab & Chemical Expo
    Not Confirmed
    arrow

    FDA Audited

    USA
    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed

    District Decision : Voluntary Action Indicated

    Inspection End Date : 2015-09-10

    BrightGene Bio-Medical Technology Co.,Ltd

    City : Suzhou

    State :

    Country/Area : CN

    Zip :

    District : ORA

    Center : CVM

    Project Area : Monitoring of Marketed Animal Dr...

    District Decision : Voluntary Action Indicated

    Inspection End Date : 2015-09-10

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    ABOUT THIS PAGE

    Contact BrightGene Bio-Medical Technology Co Ltd and get a quotation

    BrightGene Bio-Medical Technology Co Ltd is a supplier offers 67 products (APIs, Excipients or Intermediates).

    Find a price of Entecavir bulk with DMF, CEP, JDMF offered by BrightGene Bio-Medical Technology Co Ltd

    Find a price of Everolimus bulk with DMF, CEP, JDMF offered by BrightGene Bio-Medical Technology Co Ltd

    Find a price of Argatroban bulk with DMF, JDMF offered by BrightGene Bio-Medical Technology Co Ltd

    Find a price of Eribulin bulk with DMF, JDMF offered by BrightGene Bio-Medical Technology Co Ltd

    Find a price of Micafungin bulk with DMF, JDMF offered by BrightGene Bio-Medical Technology Co Ltd

    Find a price of Oseltamivir Phosphate bulk with DMF, CEP offered by BrightGene Bio-Medical Technology Co Ltd

    Find a price of Sugammadex Sodium bulk with DMF, JDMF offered by BrightGene Bio-Medical Technology Co Ltd

    Find a price of Anidulafungin bulk with DMF offered by BrightGene Bio-Medical Technology Co Ltd

    Find a price of Ansamitocin P3 bulk with DMF offered by BrightGene Bio-Medical Technology Co Ltd

    Find a price of Argatroban bulk with JDMF offered by BrightGene Bio-Medical Technology Co Ltd

    Find a price of Carboprost Tromethamine bulk with DMF offered by BrightGene Bio-Medical Technology Co Ltd

    Find a price of CAS 184177-83-1 bulk with DMF offered by BrightGene Bio-Medical Technology Co Ltd

    Find a price of CAS 361440-67-7 bulk with DMF offered by BrightGene Bio-Medical Technology Co Ltd

    Find a price of CAS-149809-43-8 bulk with DMF offered by BrightGene Bio-Medical Technology Co Ltd

    Find a price of Caspofungin bulk with DMF offered by BrightGene Bio-Medical Technology Co Ltd

    Find a price of Dalbavancin bulk with DMF offered by BrightGene Bio-Medical Technology Co Ltd

    Find a price of Entecavir Intermediate VIII Isomer bulk with DMF offered by BrightGene Bio-Medical Technology Co Ltd

    Find a price of Everolimus bulk with DMF offered by BrightGene Bio-Medical Technology Co Ltd

    Find a price of Exatecan bulk with DMF offered by BrightGene Bio-Medical Technology Co Ltd

    Find a price of Ferric Carboxymaltose bulk with DMF offered by BrightGene Bio-Medical Technology Co Ltd

    Find a price of Fidaxomicin bulk with DMF offered by BrightGene Bio-Medical Technology Co Ltd

    Find a price of Fondaparinux Sodium bulk with DMF offered by BrightGene Bio-Medical Technology Co Ltd

    Find a price of Hydroxy Echinocandin bulk with DMF offered by BrightGene Bio-Medical Technology Co Ltd

    Find a price of Isavuconazonium Sulfate bulk with DMF offered by BrightGene Bio-Medical Technology Co Ltd

    Find a price of Lurbinectedin bulk with DMF offered by BrightGene Bio-Medical Technology Co Ltd

    Find a price of Maytansinoid DM1 bulk with DMF offered by BrightGene Bio-Medical Technology Co Ltd

    Find a price of Micafungin bulk with JDMF offered by BrightGene Bio-Medical Technology Co Ltd

    Find a price of Midostaurin bulk with DMF offered by BrightGene Bio-Medical Technology Co Ltd

    Find a price of Molnupiravir bulk with DMF offered by BrightGene Bio-Medical Technology Co Ltd

    Find a price of Nicergoline bulk with CEP offered by BrightGene Bio-Medical Technology Co Ltd

    Find a price of Obeticholic Acid bulk with DMF offered by BrightGene Bio-Medical Technology Co Ltd

    Find a price of Pemetrexed bulk with DMF offered by BrightGene Bio-Medical Technology Co Ltd

    Find a price of Pimecrolimus bulk with DMF offered by BrightGene Bio-Medical Technology Co Ltd

    Find a price of Posaconazole bulk with DMF offered by BrightGene Bio-Medical Technology Co Ltd

    Find a price of Selamectin bulk with CEP offered by BrightGene Bio-Medical Technology Co Ltd

    Find a price of Sirolimus bulk with DMF offered by BrightGene Bio-Medical Technology Co Ltd

    Find a price of Spinosyn D bulk with DMF offered by BrightGene Bio-Medical Technology Co Ltd

    Find a price of Trabectedin bulk with DMF offered by BrightGene Bio-Medical Technology Co Ltd

    Find a price of Trientine Hydrochloride bulk with DMF offered by BrightGene Bio-Medical Technology Co Ltd

    Find a price of Voclosporin bulk with DMF offered by BrightGene Bio-Medical Technology Co Ltd

    Find a price of Staurosporine bulk offered by BrightGene Bio-Medical Technology Co Ltd

    Find a price of Amphotericin B bulk offered by BrightGene Bio-Medical Technology Co Ltd

    Find a price of Apalutamide bulk offered by BrightGene Bio-Medical Technology Co Ltd

    Find a price of Cabergoline bulk offered by BrightGene Bio-Medical Technology Co Ltd

    Find a price of Dienogest bulk offered by BrightGene Bio-Medical Technology Co Ltd

    Find a price of Doramectin bulk offered by BrightGene Bio-Medical Technology Co Ltd

    Find a price of Dydrogesterone bulk offered by BrightGene Bio-Medical Technology Co Ltd

    Find a price of Eldecalcitol bulk offered by BrightGene Bio-Medical Technology Co Ltd

    Find a price of Emodepside bulk offered by BrightGene Bio-Medical Technology Co Ltd

    Find a price of Entecavir Monohydrate bulk offered by BrightGene Bio-Medical Technology Co Ltd

    Find a price of Ferric Pyrophosphate Citrate bulk offered by BrightGene Bio-Medical Technology Co Ltd

    Find a price of Fluralaner bulk offered by BrightGene Bio-Medical Technology Co Ltd

    Find a price of Gadobutrol bulk offered by BrightGene Bio-Medical Technology Co Ltd

    Find a price of Ibrexafungerp Citrate bulk offered by BrightGene Bio-Medical Technology Co Ltd

    Find a price of Iodixanol bulk offered by BrightGene Bio-Medical Technology Co Ltd

    Find a price of Iomeprol bulk offered by BrightGene Bio-Medical Technology Co Ltd

    Find a price of Iopromide bulk offered by BrightGene Bio-Medical Technology Co Ltd

    Find a price of Iron Sucrose bulk offered by BrightGene Bio-Medical Technology Co Ltd

    Find a price of Josamycin bulk offered by BrightGene Bio-Medical Technology Co Ltd

    Find a price of Laninamivir Octanoate bulk offered by BrightGene Bio-Medical Technology Co Ltd

    Find a price of Mycophenolate Sodium bulk offered by BrightGene Bio-Medical Technology Co Ltd

    Find a price of Nystatin bulk offered by BrightGene Bio-Medical Technology Co Ltd

    Find a price of Omadacycline bulk offered by BrightGene Bio-Medical Technology Co Ltd

    Find a price of Oritavancin bulk offered by BrightGene Bio-Medical Technology Co Ltd

    Find a price of Regadenoson Monohydrate bulk offered by BrightGene Bio-Medical Technology Co Ltd

    Find a price of Relugolix bulk offered by BrightGene Bio-Medical Technology Co Ltd

    Find a price of Tacrolimus bulk offered by BrightGene Bio-Medical Technology Co Ltd

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search